Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
The influence of ethnicity on the characteristics of multiple sclerosis: A local population study between Persians and Arabs.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
3D models of human ERα and ERβ complexed with coumestrol.
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Physiopathology of symptoms and signs in multiple sclerosis.
Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research.
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Amiloride Clinical Trial In Optic Neuritis (ACTION)
Vivitrol dosing and administration
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Safety Study of GNbAC1 in Multiple Sclerosis Patients

Pages